The Influence of Angiotensin Peptides on Survival and Motility of Human High-Grade Serous Ovarian Cancer Cells in Serum Starvation Conditions

High-grade serous ovarian carcinoma (HGSOC) is the most frequent and malignant form of ovarian cancer. A local renin–angiotensin system (RAS) has been found in the ovary, and changes in selected components of this system were observed in pathological states and also in ovarian cancer. In the present study, we examined the effect of three peptides, Ang-(1-7), Ang-(1-9) and Ang-(3-7), on proliferation and motility of the OVPA8 cell line, a new well-defined and preclinical model of HGSOC. We confirmed the presence of mRNA for all angiotensin receptors in the tested cells. Furthermore, our findings indicate that all tested angiotensin peptides increased the metabolic serum in the medium by activation of cell defense mechanisms such as nuclear factor kappaB signaling pathway andapoptosis. Moreover, tested angiotensin peptides intensified serum starvation-induced cell cycle arrest at the G0/G1 phase. In the case of Ang-(3-7), a significant decrease in the number of Ki67 positive cells (Ki67+) and reduced percentage of activated ERK1/2 levels in ovarian cancer cells were additionally reported. The angiotensin-induced effect of the accumulation of cells in the G0/G1 phase was not observed in OVPA8 cells growing on the medium with 10% FBS. Moreover, in the case of Ang-(3-7), the tendency was quite the opposite. Ang-(1-7) but not Ang-(1-9) or Ang-(3-7) increased the mobility of reluctant-to-migrate OVAP8 cells cultured in the serum-free medium. In any cases, the changes in the expression of VIM and HIF1A gene, associated with epithelial–mesenchymal transition (EMT), were not observed. In conclusion, we speculate that the adaptation to starvation in nutrient-deprived tumors can be modulated by peptides from the renin–angiotensin system. The influence of angiotensin peptides on cancer cells is highly dependent on the availability of growth factors and nutrients.     

4-(对甲氧基苯基)-7-甲氧基-1-羟基-3-萘甲酸的合成研究

4－（对甲氧基苯基）－7－甲氧基－1－羟基－3－萘甲酸是一种新药物的中间体,它由茴香酸和茴香醚经Friedel-Crafts（付克）反应;再与丁二酸二乙酯在叔丁醇钾的碱中缩合,脱水;然后经分子内的付克反应成环;后者在相转移催化剂（PTC）存在下水解得目标产物,总产率达41．9％,产品纯度达99．7％。     

Angiotensin-(1-7) Prevents Lipopolysaccharide-Induced Autophagy via the Mas Receptor in Skeletal Muscle

Skeletal muscle atrophy, which occurs in lipopolysaccharide (LPS)-induced sepsis, causes a severe muscle function reduction. The increased autophagy contributes to sepsis-induced skeletal muscle atrophy in a model of LPS injection, increasing LC3II/LC3I ratio, autophagy flux, and autophagosomes. Angiotensin-(1-7) (Ang-(1-7)) has anti-atrophic effects via the Mas receptor in skeletal muscle. However, the impact of Ang-(1-7) on LPS-induced autophagy is unknown. In this study, we determined the effect of Ang-(1-7) on sepsis-induced muscle autophagy. C57BL6 wild-type (WT) mice and mice lacking the Mas receptor (KO Mas) were injected with LPS together with the systemic administration of Ang-(1-7) to determine autophagy in skeletal muscle. We also evaluated autophagy and p38 and c-Jun N-terminal kinase (JNK)activation. Our results show that Ang-(1-7) prevents LPS-induced autophagy in the diaphragm, tibialis anterior, and gastrocnemius of WT mice, which is demonstrated by a decrease in the LC3II/LC3I ratio and mRNA levels of lc3b and ctsl. This effect was lost in KO Mas mice, suggesting the role of the Mas receptor. The results in C2C12 cells show that Ang-(1-7) reduces several LPS-dependent effects, such as autophagy (LC3II/LC3I ratio, autophagic flux, and autophagosomes), activation of p38 and JNK, B-cell lymphoma-2 (BCL2) phosphorylation, and disassembly of the Beclin1/BCL2 complex. In conclusion, Ang-(1-7)/Mas receptor reduces LPS-induced autophagy in skeletal muscle. In vitro assays indicate that Ang-(1-7) prevents LPS-induced autophagy and modifies the MAPK signaling and the disassembly of a complex involved at the beginning of autophagy.     

1-(5-萘酚7-磺酸)-3-[4-(苯基偶氮)苯基]-三氮烯-溴化十四烷基吡啶- 阴离子表面活性剂显色反应研究

介绍了在NaOH介质中，阳离子表面活性剂溴化十四烷基吡啶(TPB)存在下，1—(5—萘酚—7—磺酸)—3—[4—(苯基偶氮)苯基]—三氮烯(NASAPAPT)与阴离子表面活性剂(AS)的显色反应。该显色反应显色快，稳定，显色配合物最大吸收位于594nm，显色剂与阴离子表面活性剂配合比为1：3。研究的方法用于实样分析。     

3-(S)-(-)-(1-氨甲酰基-1,1-二苯基甲基)吡咯烷的制备

3-(S)-(-)-1-氨甲酰基-1,1-二苯基甲基)吡咯烷是合成抗尿失禁药物达非那新的重要中间体。它由3-(S)-( )-3-羟基吡咯烷盐酸盐经磺酰化和烷基化反应得到3-(S)-( )-(1-氰基-1,1-二苯基甲基)-1-甲苯磺酰基吡咯烷,再经过去磺酰化和水解4步反应制得,总产率为5.1%。     

1-(5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-基)-3-(吡啶-3-基甲基)脲的合成

以5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酸与二氯亚砜为起始原料,经酰氯化反应、酰胺反应、霍夫曼重排以及水解反应生成中间体5-(4-氯苯基)-1-(2,4-二氯苯基)-3-氨基-4-甲基-1H-吡唑,再经过与氯甲酸苯酯反应、胺酯交换反应得到标题化合物,其结构经1HNMR、MS谱确证,总收率26.9%。     

4-溴-1-溴甲基-2-对氯苯基-5-三氟甲基吡咯-3-腈的合成

以2 对氯苯基1 甲基5 三氟甲基2 吡咯啉3 腈为原料,经三步反应合成了4 溴1溴甲基2 对氯苯基5 三氟甲基吡咯3 腈,合成总收率为29.8%。     

旋毛虫感染诱导的小鼠乳腺癌MCF-7细胞基因表达的变化

目的构建旋毛虫感染诱导的小鼠乳腺癌MCF-7细胞基因表达变化的cDNA消减文库,探讨旋毛虫感染诱导的MCF-7细胞基因表达的变化。方法复制MCF-7细胞小鼠模型,设对照组和旋毛虫感染组(实验组),采用抑制性消减杂交技术构建旋毛虫感染诱导的MCF-7细胞上调基因表达消减文库,并利用反向Northernblot技术对所获得基因的特异性表达进行验证。结果成功构建了旋毛虫感染诱导的MCF-7细胞上调基因表达消减文库,克隆的目的基因片段大小分布在200～500bp之间,20个阳性克隆的测序结果经BLAST比对,获得差异表达的已知功能基因8个和未知功能基因4个,这些基因在小鼠乳腺癌细胞中均有表达,而在肌肉组织中无表达。结论旋毛虫感染诱导的MCF-7细胞差异表达基因上调,其中RB基因可能与乳腺癌细胞的生长抑制密切相关,为在基因水平研究旋毛虫抗肿瘤机理奠定了基础。     

Reversible addition-fragmentation chain transfer polymerization of 7-(4-(acryloyloxy)butoxy)coumarin

The light sensitive vinyl monomer with coumarin unit, 7-(4-(acryloyloxy)butoxy)coumarin (7AC), was synthesized. The reversible addition-fragmentation chain transfer (RAFT) polymerization of 7AC, initiated by 2,2′-azobisisobutyronitrile (AIBN), was carried out using 2-cyanoprop-2-yl dithiobenzoate (CPDB) as a RAFT agent in N,N-dimethylformamide (DMF) solution. The kinetics exhibited first-order relationship with respect to the monomer concentration. The molecular weight of the polymer increased linearly with the monomer conversion. The chain extension of poly(7-(4-(acryloyloxy)butoxy)coumarin) (P7AC) using styrene (St) as the second monomer demonstrated that the obtained polymers were almost “living”. The fluorescence intensity of P7AC increased with the molecular weight of P7AC and was stronger than that of the monomer. The obtained polymer had strong ultraviolet (UV) absorption at 322 nm. The molecular weights of the polymer had no effect on its ultraviolet absorption intensity. The coumarin structure existing in P7AC underwent [2 + 2] cycloaddition reaction (photodimerization) under UV irradiation in tetrahydrofuran (THF) solution, which can be further used to prepare small particles from the single polymer.     

1-(3-氨基苯基)-3-(4-氨基苯基)-2-丙烯-1-酮的合成

以对乙酰氨基苯甲醛、间乙酰氨基苯乙酮为原料经两步反应合成具有光敏性能的1 (3 氨基苯基) 3 (4 氨基苯基) 2 丙烯 1 酮。通过优化实验得到最佳的合成工艺条件为:对乙酰氨基苯甲醛、间乙酰氨基苯乙酮在温度为0℃下,以乙醇为溶剂、氢氧化钠为催化剂,进行羟醛缩合反应3h。分离提纯后,加入盐酸溶液在100℃下水解3h,产物经重结晶提纯。总收率达到61 9%,较1998年的文献[6]提高39 3%。并对产物的结构进行了表征。     

1-(2-氯苯基)-2-(4-氟苯基)-3-溴-1-丙烯的合成

1-(2-氯苯基)-2-(4-氟苯基)-3-溴-1-丙烯(2)是氟环唑的关键中间体。以1,2-二氯乙烷和水为溶剂,1-(2-氯苯基)-2-(4-氟苯基)-1-丙烯(1)在氢溴酸/双氧水体系中发生α-溴代反应得到该化合物。通过使用氢溴酸/双氧水代替溴素或N-溴代丁二酰亚胺,提高了溴的利用率及产品的收率,避免了烯烃的加成,减少了副反应的发生,减少了三废。通过实验获得了反应的优惠条件:二氯乙烷和水为溶剂,回流反应,n(1)∶n(HBr)∶n(H2O2)=1∶1.1∶2.5,氢溴酸和双氧水的滴加时间为6 h,在上述反应条件下,反应收率为90.6%,选择性90.6%。     

1-环丙基-7-氯-6-(1-哌嗪基)-4-氧-1,4-二氢-3-喹啉羧酸盐酸盐的熔化与离解性质研究

1－环丙基－7－氯－6－（1－哌嗪基）－4－氧－1，4－二氢－3－喹啉羧酸盐酸盐为环丙沙星合成中主要的杂质之一，研究其物化性质对于改善环丙沙星的结晶分离提纯具有重要意义。本文研究了1－环丙基－7－氯－6－（1－哌嗪基）－4－氧－1，4－二氢－3－喹啉羧酸盐酸盐的熔化，分解特性，溶解度与离子强度，温度和pH值的关系，并测定了该物质的离解常数，估算了该物质在水溶液中的活度积。     

1-(2-氟苯基)-1-(4-氟苯基)环氧乙烷的合成研究

以2,4’-二氟二苯酮和锍盐(CH3)3SHSO4为原料,在碱性条件下反应生成1-(2-氟苯基)-1-(4-氟苯基)环氧乙烷。通过正交实验确定最佳工艺条件为:氢氧化钾、甲醇和2,4’-二氟二苯酮的物质的量比为6∶1.25∶1,反应温度45℃。以2,4’-二氟二苯酮计,产品收率为91.23%,含量为97.45%。     

不对称催化合成(R)-(+)-3′-氯-苯丙醇

[目的](R)-(+)-3′-氯-苯丙醇是一种手性农药中间体和应用于预防治疗葡萄孢菌所致的灰霉病的有效植物抗菌素,旨在研究一条产品光学纯度高的工艺路线。[方法]以间氯苯丙酮为原料、以铱催化剂和双胺膦手性配体对3′-氯-苯丙酮进行不对称催化加氢还原制备(R)-(+)-3′-氯-苯丙醇。[结果]通过正交试验优化,反应转化率95%以上,产品光学纯度93%e.e.值。[结论]该路线反应条件温和、转化率和光学纯度高,可用于工业生产。     

4-(5-甲醛基-2-噻吩基)-7-(2-噻吩基)[2,1,3]苯并噻二唑的合成

采用两种不同的途径合成了4-(5-甲醛基-2-噻吩基)-7-(2-噻吩基)[2,l,3]苯并噻二唑。研究结果表明,DMF/POCl3体系较n-BuLi/DMF体系产率更高。改变两种合成途径的反应条件,或用单醛化产物进一步醛化,均未发现二醛取代产物的生成。     

TRFIA螯合剂中间体2,6-二(3′-溴甲基-1′-吡唑基)-4-溴吡啶的合成、分离与表征

以2,6-二（3-甲基-1-H-吡唑基）-4-溴吡啶为原料,经重氮化、溴化合成了新型时间分辨荧光免疫分析（TR-FIA）双功能螯合剂中间体2,6-二（3＇-溴甲基-1＇-吡唑基）-4-溴吡啶,通过IR、GC-MS1、HNMR和元素分析等对其结构进行了确认,探讨了合成条件及反应机理。同时,通过GC-MS1、HNMR和元素分析等对第一副产物4-溴-2-（3＇-溴甲基-1＇-吡唑基）-6-（3＇-甲基-1＇-吡唑基）吡啶的结构也进行了确认,以其为原料可继续合成目标化合物,大幅提高总产率。     

N-[4-(间甲基苯甲酰基哌嗪)乙酰基]-N-甲基-3-(1-萘氧基)-3-(2-噻吩基)-丙胺的合成

以N-甲基-3-(1-萘氧基)-3-(2-噻吩基)-丙胺(Duloxetine)为原料,合成了标题化合物.中间体和产物的结构经 ~1HNMR、IR和质谱表征.     

3-(S)-巯基-1-(N-对硝基苄氧羰基乙酰亚胺)四氢吡咯的合成

对标题化合物的合成工艺作了改进。以L-羟基脯氨酸为原料,环己酮作催化剂,经脱羧获得的3-(R)-羟基四氢吡咯盐酸盐,与由乙醇和乙腈反应得到的乙氧基乙酰亚胺盐酸盐,经5步反应成功地合成了目标产物,总收率为15.6%,关键中间体及目标化合物经过1HNMR检测,还探讨了标题化合物及其前体的构型转化问题。     

铕（III）-1-（氯苯基）-3-（2-羟基苯基）-丙二酮类配合物的合成与荧光性质

合成了1-(邻氯苯基)-3-(2-羟基苯基)-丙二酮(L1)、1-(间氯苯基)-3-(2-羟基苯基)-丙二酮(L2)和1-(对氯苯基)-3-(2-羟基苯基)-丙二酮(L3)3种配体,并将此3种配体分别与 Eu(III)反应生成3种新的稀土配合物。运用元素分析、红外光谱与荧光光谱等手段对配合物进行了表征。结果表明：3种配合物的组成分别为 Eu(L1)3·2H2O、Eu(L2)3·2H2O 和 Eu(L3)3·2H2O。荧光光谱显示,3种配合物的配体均能将吸收的能量有效地传递给三价铕离子,从而使配合物发射出强的铕离子的特征荧光。在3种配合物中,Eu(L1)3·2H2O 的荧光强度远大于 Eu(L2)3·2H2O 和 Eu(L3)3·2H2O 的荧光强度,这说明配体 L1与 Eu(III)离子的能级匹配较好,能量传递效率较高。     

2-(2-氯苄基)-2-(1-氯环丙基)环氧乙烷的合成

报道了丙硫菌唑中间体2-(2-氯苄基)-2-(1-氯环丙基)环氧乙烷的合成方法。以1-氯-N,N-二甲基环丙基甲酰胺和邻氯氯苄为原料,经格氏反应制备2-氯苄基-(1-氯环丙基)酮;后者再与硫叶立德试剂反应得到相应的环氧化物。